Clinical Trials Logo

Filter by:
NCT ID: NCT05751850 Recruiting - Clinical trials for First-line Treatment of Advanced Pancreatic Cancer

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Start date: June 13, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.

NCT ID: NCT05751733 Recruiting - Clinical trials for Gastrointestinal Stromal Tumors

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The goal of this Mesylate apatinib versus standard second-line TKI in the treatment of advanced gastrointestinal stromal tumors: a randomized, open, controlled, single-center clinical study is to explore the efficacy and safety of Apatinib compared with second-line treatment in advanced GIST patients with first-line TKI failure. The main questions it aims to answer are: - To explore the efficacy and safety of Apatinib compared with standard second-line treatment for GIST with advanced first-line TKI failure. - To explore the expression level and MVD value of VEGFR2 in GIST, and to explore the relationship between the expression level and the location, size, mitotic image and recurrence risk grading of GIST. Patients with advanced GIST were randomly included in the trial group and the control group at a ratio of 1:1.

NCT ID: NCT05751486 Recruiting - Clinical trials for Advanced Nasopharyngeal Carcinoma

A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

Start date: October 21, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS001sc monotherapy and combination with gemcitabine and cisplatin (GP) in patients with Advanced nasopharyngeal carcinoma.

NCT ID: NCT05751356 Recruiting - Clinical trials for Advanced Solid Tumor

TR128 in Patients With Advanced Solid Tumors

Start date: February 23, 2024
Phase: Phase 1
Study type: Interventional

This is a open-label, 3+3 design, dose escalation and expansion, phase I study, to evaluate the safety and tolerability, and to determine the Recommended Phase II Dose (RP2D) of TR128 when administered qd in patients with advanced solid tumors. Up to 5 cohorts of 3-6 patients each will be treated in dose escalation phase of the study. One cycle is 28 days. Dose expansion phase to further evaluate the safety, tolerability and preliminary anti-tumor activity of TR128 at the RP2D.

NCT ID: NCT05751343 Recruiting - Clinical trials for Hepatocellular Carcinoma

TACE-HAIC Plus Atezolizumab and Bevacizumab for Unresectable HCC: a Phase 2 Clinical Trial

Start date: March 9, 2023
Phase: Phase 2
Study type: Interventional

Transartial chemobolization plus hepatic artery infusion chemotherapy showed performance for unresectable hepatocellular carcinoma (HCC). Whether the additional of atezolizumab plus bevacizumab will improve the response rate for those patients is still unknown. This phase 2 clinical trial aims to investigate the objective response rate for unresectable hepatocellular carcinoma.

NCT ID: NCT05751187 Recruiting - Non-squamous NSCLC Clinical Trials

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

Start date: June 27, 2023
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy and safety of Pembrolizumab in combination with Bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.

NCT ID: NCT05751018 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

Start date: December 8, 2021
Phase: Phase 2
Study type: Interventional

This is a multicenter, single-arm phase II clinical study to evaluate the safety and efficacy of pyrotinib maleate as a first-line treatment for HER2-mutated or amplified non-small cell lung cancer. Pyrotinib maleate is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.

NCT ID: NCT05750771 Recruiting - Clinical trials for Coronary Artery Disease

Comparison of DCB and DES for Severe Calcification of de Novo Lesion in Elderly CHD

Start date: February 20, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial was to compare the effectiveness of drug balloons versus drug-coated stents in calcified lesions in elderly coronary artery disease. The main question it aims to answer is whether the application of DCB is non-inferior to DES for in situ large vessel calcified lesions in the elderly coronary arteries. And to develop a method to precisely identify the nature and extent of calcified lesions and to rationalize the choice of pretreatment.

NCT ID: NCT05750082 Recruiting - Clinical trials for Coronary Artery Disease Acute Coronary Syndrome Myocardial Ischemia Plaque Characterization

The AIPLAQUE Study: An Artificial Intelligence-based Prospective Study to Analyze PLAQUE Using CCTA

Start date: April 12, 2021
Phase:
Study type: Observational

This trial is a single-center, prospective, observational clinical study. All patients who have at least one coronary artery stenosis of 30%-90% in diameter ≥ 2mm confirmed by CCTA, and who are scheduled to undergo clinically indicated invasive coronary angiography (ICA) and optical coherence tomography (OCT) evaluation and/or treatment will be eligible for enrollment. We proposed a novel approach that integrates CCTA, ICA and OCT images to automatically measure plaque characterization and calculate CT-FFR using computational fluid dynamics (CFD) simulation and artificial intelligence deep learning.

NCT ID: NCT05749978 Recruiting - Asana Adjustment Clinical Trials

Effects of Postural Adjustment on Hemodynamics in Patients Undergoing Prone Spine Surgery Under General Anesthesia

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The prone position is a special position often used for spinal surgery. As a special position of general anesthesia, after induction of general anesthesia, severe hemodynamic fluctuations often occur when the supine position is changed to the prone position, which seriously affects the patient's circulatory and respiratory functions.